Entomologist Donald Barnard demonstrates the attraction of female yellow fever mosquitoes to his hand in an olfactometer. The olfactometer contains a screen separating the attractant (in this case, his hand) from the mosquitoes
Find information on thousands of medical conditions and prescription drugs.

Yellow fever

Yellow fever (also called yellow jack, black vomit, or sometimes American Plague) is an acute viral disease. It is still an important cause of hemorrhagic illness in several African and South American countries despite existence of an effective vaccine. In the past it was a source of several devastating epidemics. As of 2005, the World Health Organization (WHO) estimates that yellow fever causes 200,000 illnesses and 30,000 deaths every year in unvaccinated populations. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Yaws
Yellow fever
Yellow nail syndrome
Yersinia pestis
Yersiniosis
Yolk sac tumor
Z
Medicines

The disease is caused by an arbovirus of the family Flaviviridae, and is one of the smallest RNA viruses isolated by man.

Mosquitos are the primary vector in transmission of the disease from forest monkeys to humans and in person-to-person transmission. The mosquitos involved are Aedes simpsoni, Aedes africanus, and Aedes aegypti in Africa; and the Haemagogus and Sabethes genera.

The disease can remain locally unknown in humans for long periods of time and then suddenly break out in an epidemic fashion. In Central America and Trinidad this has been due to a form of the disease ("Jungle Yellow Fever") which is kept alive in Red Howler monkey populations and transmitted by Haemagogus mosquito species which only live in the canopy of rainforests. It is passed to humans when the tall rainforest trees are cut down. Infected woodcutters can then pass on the disease to others via species of Aedes mosquitoes which typically live at low altitudes, thus triggering an epidemic.

The course of the disease varies from an unapparent infection to an intense feverish illness with high mortality rate. There is a difference between disease outbreaks in rural or forest areas and in towns. Disease outbreaks in towns and non-native people are usually more serious.

After a 3 to 6 day incubation period the typical symptoms that arise are fever, muscle aches, headache and backache. Other symptoms may include a red tongue, flushed face, and reddening of the eyes. In a proportion of cases there is also involvement of internal organs - liver, kidneys and the heart. There may be hemorrhage from the digestive tract (bloody vomit). Later the disease is sometimes complicated by jaundice with liver failure (which causes yellow skin colour, hence the name "Yellow fever") and/or kidney insufficiency with proteinuria. If the disease progresses, delirium, seizures and coma ensue. Hypotension and dehydration are also common. Mortality is around 5%; although historically it has been much higher , .Patients who die usually do so within six to seven days from the onset.

Prevention

A vaccine for yellow fever was developed which gives a 10-year+ immunity from the disease and effectively protects people traveling to the affected areas whilst being a means to control the disease at the same time. Woodcutters working in jungle areas should be particularly targeted for vaccination. Insecticides, protective clothing and screening of houses are helpful but not always enough. In affected areas mosquito control methods have proved effective in decreasing the number of cases.

Public health

Yellow fever is one of the few diseases where some countries have a legal requirement that travellers to an endemic area require vaccination. These countries also usually have regulations requiring quarantine for people who arrive from yellow fever endemic areas who do not provide evidence of their having being vaccinated against yellow fever. This is because one of the vectors for transmission of yellow fever, the Aedes mosquito, exists in other tropical parts of the world (which are not endemic for yellow fever) and an outbreak could potentially erupt if the disease is inadvertently brought in

Read more at Wikipedia.org


[List your site here Free!]


Yellow fever virus infectivity for Bolivian Aedes aegypti mosquitoes
From Emerging Infectious Diseases, 9/1/04 by John-Paul Mutebi

The absence of urban yellow fever virus (YFV) in Bolivian cities has been attributed to the lack of competent urban mosquito vectors. Experiments with Aedes aegypti from Santa Cruz, Bolivia, demonstrated infection (100%), dissemination (20%), and transmission of a Bolivian YFV strain (CENETROP-322).

**********

Yellow fever virus (YFV) may cause severe hemorrhagic fever in humans. The virus is transmitted between susceptible vertebrate hosts by infected mosquitoes ill the genera Aedes, Haemagogus, or Sabethes (1). In the Americas, YFV occurs in two transmission cycles. In the jungle/sylvatic cycle, the virus is transmitted between susceptible monkeys, and possibly other vertebrates, by tree-hole breeding mosquitoes (1). Jungle yellow fever (YF) cases occur when these infected vectors feed on susceptible humans. In the urban cycle, YFV is transmitted to humans by Aedes aegvpti mosquitoes (1). In 2003, a total of 226 cases of jungle YF were reported from South America to the Pan American Health Organization, and as of June 23, ongoing outbreaks in Bolivia, Brazil, Colombia, and Peru during 2004 have thus far resulted in 86 confirmed cases and 41 deaths (2).

An Ae. aegypti eradication campaign initiated by the Pan American Sanitary Bureau in 1947 eliminated this species from most of Central and South America, and urban YF disappeared from the Americas in the 1940s. However, during the past 20 years, many countries abandoned Ac. aegypti control measures, and this urban vector now reoccupies almost the entire area of its distribution preeradication (1). Ac. aegypti was eradicated from Bolivia during the 1960s and 1970s but reappeared in the city of Santa Cruz in 1980, and epidemics of dengue fever occurred during the 1980s and 1990s (3). In 1997 to 1998, six cases of YF were reported among Santa Cruz residents, and some were regarded as urban YF cases (3); despite a population >1 million, low vaccine immunization cover age, and the presence of Ac. aegypti (3), no urban YF outbreak occurred. Based on these observations, researchers have suggested that sylvan strains of YFV circulating in Bolivia may not be infective for Bolivian Ae. aegypti. This study examined that hypothesis and the infectivity of a Bolivian strain of YFV for Bolivian Ae. aegypti.

The Study

All work involving infectious YFV was performed in biosafety level 3 facilities at the University of Texas Medical Branch. Three human isolates of YFV were used: CENETROP-322 (La Paz Department, Bolivia, 1999), Jimenez (Panama, 1974), and Asibi (Ghana, 1927). To facilitate transmission from a viremic vertebrate, viruses were adapted by serial passage through Syrian golden hamsters (Mesocricetus auratus), following the model of Tesh et al. (4,5); CENETROP-322 and Jimenez were passaged 11 times, and the Asibi strain was passaged 10 limes.

The SC strain of Ac. aegypti was started with mosquitoes collected from Santa Cruz, Bolivia, in 2001. Mosquitoes used in this experiment were from laboratory-reared F2-F3 generation. The REX-D strain, an old laboratory colony originally started with mosquitoes collected in Rexville, Puerto Rico and of previously defined susceptibility to YFV infection (6) was used as a control. Mosquitoes were maintained as previously described (7).

Three hamsters were injected intraperitoneally (IP) with 100 [micro]L of clarified liver homogenate, which contained approximately [10.sup.6] [log.sub.10] tissue culture infectious dose 50% (TCI[D.sub.50]/mL) of each YFV strain. Three days after infection, when viremia levels have been shown to peak (4), hamsters were anesthetized (50 mg Pentobarb/kg I P) and simultaneously exposed to 10-day-old Ac. aegypti SC or REX-D mosquitoes for 1 h. Fully engorged mosquitoes in each group were placed in separate cages and incubated for 15 days at 28[degrees]C and 80% relative humidity on a diet of 10% sucrose. Hamster blood samples were collected immediately afterward and stored at -80[degrees]C for viral assay.

Virus Transmission

At day 15 after infection, mosquitoes were allowed to feed on 8-day-old mice. (Mice were used in preference to adult hamsters because they are more susceptible to fatal infection.) After feeding, mosquitoes were assayed for YFV infection and dissemination by whole-body titration and immunofluorescence assay (IFA) of head-squash material, respectively (7). For IFA, a broadly reactive anti-flavivirus monoclonal antibody (813) with biotin-streptavidin amplification was used (8). Suckling mice were observed for illness and death. The brains of two paralyzed mice were tested for viral antigen by culturing on Vero cells. At day 14 after exposure, serum specimens from surviving mice were tested for anti-YFV antibodies by hemagglutination inhibition (Hl) test (9).

All three strains of YFV caused viremia in hamsters on day 3 after infection, with titers of 8.5, 8.7, and 7.3 TCI[D.sub.50][log.sub.l0]/mL (CENETROP-322, Jimenez, and Asibi, respectively), as determined by assay in mosquito cell cultures (4). Determination of mosquito infection and dissemination rates showed that all YFV strains were able to infect both strains of Ac. aegypti, although infection rates varied from 15.l% to 100%. Mean total mosquito YFV titers were relatively low, but the presence of virus after 15 days, evidence of dissemination in the insect, and transmission data are all indicative of replication. At day 15 postinfection, 100% of SC Ae. aegypti were infected with CENETROP-322. Infection rates and mean viral titers for CENETROP-322 were higher in SC Ae. aegypti than in the REX-D strain (Table 1). Infection rates of CENETROP-322 and Jimenez were higher than the rate for Asibi in both mosquito strains.

Virus titers in the mosquitoes varied considerably but were lowest in REX-D strain insects infected with CENETROP-322 (Table 1). These mosquitoes had the highest dissemination rates (80.7%), which indicates little correlation between virus titer and dissemination rates. Dissemination rates were highest in the REX-D strain; but our data demonstrate that both Panamanian and Bolivian strains of YFV disseminated in Santa Cruz Ae. aegypti (Table 1).

Transmission trials used 8-day-old mice to feed mosquitoes that had ingested YFV 15 days earlier (Table 2). Five mice were used per virus strain. The reluctance of mosquitoes to feed on suckling mice precluded an evaluation of all YFV-mosquito combinations. However, HI results indicated that antibodies against YFV (320 titer, Table 2) developed in one mouse exposed to SC mosquitoes infected with CENETROP-322, which indicated transmission by the Bolivian Ae. aegvpti. In addition, Jimenez and Asibi strains of YFV were transmitted by the REX-D mosquitoes. Transmission was confirmed by recovering YFV by culture from dead mice.

Conclusions

Susceptibility to YFV infection is highly variable in mosquitoes from different locations (10-12) and may be influenced by selection (6) and colonization (13). Although the use of Bolivian mosquitoes with few laboratory-reared generations compromised our ability to use large numbers, obtaining competence data as possibly representative of wild, noncolonized, mosquitoes was important. Dissemination and transmission by Santa Cruz Ae. aegypti indicate their ability to serve as vectors for a Bolivian strain of YFV. A critical component of this study was the use of a hamster model for YFV (4). The high viremia levels in hamsters (4,5) facilitate oral infection of mosquitoes and more closely resemble natural infection than feeding the insects on artificial blood meals. Suckling mice remain useful because of their sensitivity to YFV infection.

We could argue that by passing the virus in hamsters, the virus phenotype may be altered with respect to vector infectivity. However, after equivalent passages, the infectivity of the Bolivian, Panamanian, and African strains differed. The Jimenez strain was highly infectious for Bolivian Ac. aegypti (93.5%), with a relatively high dissemination rate (34.5%). In contrast, the Asibi was relatively noninfectious for the Bolivian mosquitoes. Considering the numbers of mosquitoes and virus strains involved, we cannot conclude that this finding reflects a general trend of incompatibility between South American Ac. aegypti and YFV of African origin. However, the results obtained are in close agreement with the findings by Tabachnick et al. (12). Johnson et al. (14), using Brazilian strains of Ac. aegypti and YFV, reported similar results of 35% infection rates and 25% dissemination rates. Lourenco-de-Oliveira et al. (11,15) observed infection rates from 0% to 48.6% in Brazilian Ac. aegypti infected with Brazilian YFV. In comparison, we found higher infection rates for Panamian and Bolivian YF viruses (63.3% 100%), but this finding may reflect our use of a viremic animal to infect the mosquitoes, whereas Tabachnick et al. (12) and Johnson et al. (14) used artificially prepared blood meals. Our results also demonstrate that passaging YFV in hamsters does not compromise the ability of the virus to infect mosquitoes and that the hamster model is useful to study mosquito competence for YFV.

In conclusion, our results do not support the hypothesis that Bolivian strains of YFV cannot infect Bolivian Ae. aegypti and demonstrate that the recolonizing (after 1980) South American strains of Ac. aegypti are potential YFV vectors. The reason urban YF epidemics have not yet occurred in South America, including in the city of Santa Cruz, Bolivia, where some cases were recently reported within the city limits (3), is still unknown. The mosquito infection rates observed in our study were higher that those reported by Lourenco-de-Oliviera et al. (11), and we also demonstrated YFV transmission (albeit at a low level). Thus, if YFV were to be reintroduced into urban areas of South America, a transmission cycle could possibly be established. The absence of epidemic YF may be the result of other factors, including widespread deforestation and less opportunity for YFV to move out of the sylvatic cycle, better mosquito control, the local population's YFV vaccine status, and, possibly, heterologous antibodies to other flaviviruses such as dengue (5).

This work was funded in part by grants from U.S. Agency for International Development (511-G-00-01-00 131-00) and the National Institutes of Health (AI50175).

References

(1.) Monath TP. Yellow fever. In: Monath TP, editor. The arboviruses: epidemiology and ecology, Vol. 5. Boca Raton (FL): CRC Press; 1989. p.139-231.

(2.) Pan American Health Organization. Promoting health in the Americas. EID weekly updates. Emerging and reemerging infectious diseases, region of the Americas. Vol. 2; June 21-24, 2004 [cited 2004 Jul 13]. Available from: http://www.paho.org/English/ AD/DPC/CD/eid-eer-18-dec-2003.htm#3

(3.) Van der Stuft P, Gianella A, Pirard M, Cespedes J, Lora J, Peredo C, et al. Urbanization of yellow fever in Santa Cruz, Bolivia. Lancet. 1999;353:1558-62.

(4.) Tesh RB, Guzman H, Yravassos da Rosa APA, Vasconcelos PFC, Dias LB, Brunnell JE, et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis. 2001;183:1431-6.

(5.) Xiao S-Y, Guzman H, Travassos da Rosa APA, Zhu HB, Tesh RB. Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model of previous infection with heterologous flaviviruses. Am J Trop Med Hyg. 2003;68:695-703.

(6.) Miller BR, Mitchell CJ. Genetic selection of a flavivirus-refractory strain of the yellow fever mosquito Aedes aegypti. Am J Trop Med Hyg. 1991;45:399-407.

(7.) Higgs S, Beaty BJ. Rearing and containment of mosquitoes. In: Beaty BJ, Marquardt WC, editors. The biology of disease vectors. Niwot (CO): University Press of Colorado; 1996. p. 595-605.

(8.) Gould EA, Buckley A, Cammack N. Use of the biotin streptavidin interaction to improve flavivirus detection by immunofluorescence and ELISA tests. J Virol Methods. 1985;11:41-8.

(9.) Beaty BE, Calisher CH, Shope RE. Arboviruses. In: Schmidt NJ, Emmon RW, editors. Diagnostic procedures in viral, rickettsial and chlamidial infections. 6th edition. Washington: American Public Health Association; 1989. p.797-856.

(10.) Aitken TH, Downs WG, Shope RE. Aedes aegypti strain fitness for yellow fever virus transmission. Am J Trop Med Hyg. 1979:26;985-9.

(11.) Lourenco-de-Oliveira R, Vazeille M, de Filippis AMB, Failloux A-B. Oral susceptibility to yellow fever of Aeries aegypti from Brazil. Meta Inst Oswaldo Cruz14702837.2002;97:437-9.

(12.) Tabachnick WJ, Wallis GP, Aitken THG, Miller BR, Amato GD, Lorenz L, et al. Oral infection of Aedes aegypti with yellow fever virus: geographic variation and genetic considerations. Am J Trop Med Hyg. 1985;34:1219-24.

(13.) Lorenz L, Beaty BJ, Aitken THG, Wallis GP, Tabachnick WJ. The effect of colonization upon Aedes aegypti susceptibility to oral infection with yellow fever virus. Am J Trop Med Hyg. 1984;33:690-4.

(14.) Johnson BW, Chambers IV, Crabtree MB, Filippis AM, Vilarinhos PT, Resende MC, et al. Vector competence of Brazilian Aedes aegypti and Ae. albopictus for a Brazilian yellow lever virus isolate. Trans R Soc Trop Med Hyg. 2002:96:611-3.

(15.) Lourenco-de-Oliveira R, Vazeille M. de Filippis AMB, Failloux A-B. Aedes aegypti in Brazil: genetically differentiated populations with high susceptibility to dengue and yellow fever viruses. Trans R Soc Trop Med Hyg. 2003;98:43-54.

Address for correspondence: Stephen Higgs. Department of Pathology, and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston Texas 77555-(1609, USA; fax: 409-747-2437; email: sthiggs@utmb.edu

John-Paul Mutebi, * Alberto Gianella, ([dagger]) Amelia Travassos da Rosa, ([double dagger]) Robert B. Tesh, ([double dagger]) Alan D. T. Barrett, ([double dagger]) and Stephen Higgs ([double dagger])

* Chicago Department of Public Health, Chicago, Illinois, USA; ([dagger]) CENETROP, Santa Cruz, Bolivia; and ([double dagger]) University of Texas Medical Branch, Galveston, Texas, USA

Dr. Mutebi is a medical entomologist with the Chicago Department of Public Health. He is involved with vector-bome disease surveillance and control. His research interests include vector biology, genetics, phylogenetics, and population genetics of insect vectors.

COPYRIGHT 2004 U.S. National Center for Infectious Diseases
COPYRIGHT 2004 Gale Group

Return to Yellow fever
Home Contact Resources Exchange Links ebay